Abstract
Aim: Since 2010 that the combination of platinum / pemetrexed is approved as first line therapy for advanced (locally advanced or metastatic) nonsquamous non-small cell lung cancer (NSCLC). Our aim is to assess the effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous NSCLC in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
